Needham Maintains Buy on Inozyme Pharma, Lowers Price Target to $15

Benzinga · 03/11 11:08
Needham analyst Joseph Stringer maintains Inozyme Pharma (NASDAQ:INZY) with a Buy and lowers the price target from $23 to $15.